Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Johnson & Johnson Receives Subpoenas On Marketing Of Risperdal, Topamax and Natrecor

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Subpoenas relate to investigations into sales and marketing practices by U.S. Attorneys in Philadelphia, Boston and San Francisco.

You may also be interested in...



Lilly, AstraZeneca, Cephalon Marketing Practices Under Review By House Committee

Rep. Waxman is requesting information into the marketing of Zyprexa, Seroquel, Actiq and Fentora.

Effexor Latest Target Of U.S. Office Of Personnel Management Investigation Into Rx Marketing

OPM appears to be conducting a wide-ranging investigation into mental health drug marketing. Forest, J&J and Wyeth have received subpoenas from the agency that oversees Federal Employees Health Benefits Program.

As Seagen Matures, CEO Siegall Talks About Moving The Growth Goalposts

The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By